According to Novo Nordisk, people on Wegovy were 20% less likely to develop serious cardiovascular problems for up to five years when compared to placebo.
In a groundbreaking achievement, Novo Nordisk s obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss but has also shown a remarkable reduction in the risk of heart disease.
Popular weight loss drug Wegovy can lower the risk of major cardiovascular events such as heart attack, stroke by 20 per cent, according to the results of a major trial announced on Tuesday.Novo Nordisk's semaglutide (sold as Wegovy) is a .
Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.